Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders

In pediatric patients, the selective serotonin reuptake inhibitors (SSRIs) escitalopram and citalopram (es/citalopram) are commonly prescribed for anxiety and depressive disorders. However, pharmacogenetic studies examining CYP2C19 metabolizer status and es/citalopram treatment outcomes have largely...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stacey L. Aldrich, Ethan A. Poweleit, Cynthia A. Prows, Lisa J. Martin, Jeffrey R. Strawn, Laura B. Ramsey
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019-02-01
Colecção:Frontiers in Pharmacology
Assuntos:
pharmacogenetics
CYP2C19
SSRI (selective serotonin reuptake inhibitor)
antidepressant
anxiety disorders
depressive disorder
Acesso em linha:https://www.frontiersin.org/article/10.3389/fphar.2019.00099/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados